Improvement in margin pleases GSK’s Walmsley
This article was originally published in OTC Bulletin
GlaxoSmithKline (GSK) is making “very good progress” on improving margins at its Consumer Healthcare business, according to chief executive officer Emma Walmsley.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.